Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Hematological Disorders

Pfizer to acquire Arena Pharma; Takeda’s ...

Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology, fo...

Dec 14, 2021

Myelodysplastic Syndrome Key Pharma Players
Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Findings at ASH 2021

There has been limited progress in the approval of novel agents in MDS. It has been a long wait since the last approval of lenalidomide (Revlimid) – only approved for 5–10% (del 5q) MDS patients – was granted 13 years back. Since then, only two other companies, Celgene and Astex Pharma; could succeed in getting app...

Find More
ash-2021-annual-meeting-coverage
Major Highlights of ASH 2021 Annual Meeting: Stay abreast of the fresh developments!!

Blood cancers have seen tremendous advancements in the past few years due to the dedication of researchers pulling out all the stops to churn out therapeutic innovations intended to be of service to suffering patients. These experimentations and their upshots are always brought to us through various platforms, the ...

Find More
pharma-news-for-bluebird-bio-fda-twist-bioscience-sosei-heptares
Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M

Bluebird bio may finally get a gene therapy approved in the US Bluebird bio may get gene therapy approved in the US. The Cambridge, MA biotech declared that the FDA had accepted and given priority review for Zynteglo, its gene therapy for the rare blood disorder beta-thalassemia. The announcement sets up an expe...

Find More

More Views & Analysis

Gene-Therapy-for-Hemophilia
The Evolved Gene Therapy for Hemophilia

Hemophilia is an inherited rare disorder where blood doesn’t clot in the regular way because the person affected doesn’t make enough blood-clotting proteins (clotting factors). Without these factors, patients cannot stop bleeding when they are injured. Patients with more severe forms of the disease can experience s...

Find More

recent-pharma-biotech-news-for-prolacta-renovia-magnus-hinge-health
Magnus Medical’s tech gets breakthrough status; Prolacta develops tests for pathogens detection; Renovia gets breakthrough designation for leva system; Hinge Health secures $600M funding

Magnus Medical’s neurostimulation technology gets FDA breakthrough status to treat MDD Magnus Medical has secured a breakthrough device designation from the US Food and Drug Administration (FDA) for its neurostimulation technology for major depressive disorder (MDD) treatment. The individualised, rapid-acting...

Find More

Fda-Approved-Top-Drugs-Launched-in-2021
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies in the First Half of 2021 (H1)

Progress is driven by innovation. When it comes to developing novel medications and therapeutic biological products, the FDA's Center for Drug Evaluation and Research (CDER) assists the pharmaceutical sector at every stage of the process. CDER offers scientific and regulatory assistance needed to bring innovative m...

Find More

von-willebrand-disease-vwd-market
von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improperly. Blood contains numerous proteins that aid in blood clotting when necessary. Von Willebrand factor is one of these proteins (VWF). VWD patients have either a low level of VWF in their blood or the VWF protein does not functi...

Find More

iron-deficiency-anemia-market-size-share-trends-companies-cagr-growth-therapy-treatment-therapeutics-pipeline
Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030

Anemia is a serious cause of global health loss with over 80% of the total cases diagnosed in developing countries, according to several studies. Anemia is characterized by reduced quality of red blood cells, diminished hemoglobin levels and even altered morphology of red blood cells. The symptoms of the condition ...

Find More

recent-pharma-news-updates-for-hebabiz-pfizer-astrazeneca-bms-masimo
AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers Squibb’s Opdivo; and Masimo’s PVi

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca's 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neu...

Find More

Postoperative Pain is the pain that an individual experiences after a major operation or surgical pr.....

Find More

Though Covid-19 has a significant impact on the supply chain, input costs, logistics, and raw materi.....

Find More

Pyelonephritis (Kidney infection) is an infection of the kidney, which is a consequence of urinary t.....

Find More

Delivery of therapeutics to the human eye is among the most interesting endeavours a formulator can .....

Find More

In the ATRT market domain, presently, there are a total of 11 drugs in the pipeline, which are in di.....

Find More

Atrial fibrillation market is brimming with novel therapies in different stages of clinical developm.....

Find More